Lonza Inc.

Lonza Guangzhou Nansha Ltd.

Astrazeneca Ab

Lonza Ag

Lonza Guangzhou Research & Development Center Ltd

Laurent Ducry

Jesús Zurdo

Gayle Allway

Ramon Gomez De La Cuesta

Jin She

Heilam Wong

Bernhard Stump

Laurence Bonnafoux

Lars Arne Andreas Arnell

Martin Hans Bohlin

Dominique Roberge

Nikolaus H Bieler

Mattias Magnusson

Rhony Aufdenblatten

Ulrika Lindblad

Gayle Phillips

Antibodies having modified constant regions so as to permit conjugation of the antibody to a payload such as a therapeutic agent are described. Preferred antibodies include a mutation at light chain position 180 (positional numbering), most preferably the mutation is to a residue selected from C, K, Q, or a non-natural amino acid. Additional mutations may also be combined with a mutation at position 180; including one or more of light chain (LC) S208, LC S171, LC S182, LC A184, LC V191, LC S202, LC S203, LC T206, heavy chain (HC) S160, HC T190, HC S443, HC S447, HC S139, HC S168, HC V170, HC V176, HC T200, HC S445 according to a positional numbering convention.

CL and/or CH1 mutated antibodies for drug conjugation

Antibodies

The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; further to a process for the preparation of said protein-drug-conjugates via various intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug conjugates.

Branched linker for protein drug conjugates

The present invention relates to a process for Grignard type reactions comprising mixing at least two fluids in a microreactor having at least two injection points.

Method for grignard type reactions in microreactors

The present invention is directed to a process for the preparation of a diastereomerically pure dibenzoyl-L-tartrate salt of a compound of formula (III) and to products of said process.

Process 054

Growing community of inventors

Sierre, Switzerland

Laurent Ducry